Importantly, therapy-resistant or -persistent solid cancer cells with a mesenchymal gene signature exhibit vulnerability to GPX4 inhibition, which suggests that targeting GPX4 has therapeutic potential in certain intractable phases or types of cancers [16,17]. This evidence concerns the gene GPX4 and cancer.